Emergency Use Of Unapproved Drugs Outlined In FDA Draft Guidance
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA action on requests for consideration will likely take place within hours or days in an emergency situation, according to the draft document. The agency also encourages submission of candidate products prior to an emergency “at the earliest possible time.”
You may also be interested in...
Project BioShield Is Topic Of House Hearings July 12 And 14
Homeland Security/Emergency Preparedness Subcommittee and Government Reform Committee hearings will focus on countermeasure procurement issues and evaluating the effectiveness of the BioShield Act of 2004.
Project BioShield Is Topic Of House Hearings July 12 And 14
Homeland Security/Emergency Preparedness Subcommittee and Government Reform Committee hearings will focus on countermeasure procurement issues and evaluating the effectiveness of the BioShield Act of 2004.
FDA Grants Emergency Use Authorization For Anthrax Vaccine
The ability to opt-out of the inoculation under the Anthrax Vaccine Immunization Program is one condition of FDA’s clearance of Anthrax Vaccine Adsorbed for the prevention of inhalation anthrax. The authorization is the first use of the Emergency Use Authorization under BioShield Act of 2004.